BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 2000;32:1145-1153. [PMID: 11050068 DOI: 10.1053/jhep.2000.19622] [Cited by in Crossref: 144] [Cited by in F6Publishing: 134] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Lee C, Lu S, Changchien C, Wang J, Wang J, Hung C, Hu T. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. Journal of Hepatology 2006;44:76-82. [DOI: 10.1016/j.jhep.2005.08.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
2 Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25:97-106. [PMID: 12367644 DOI: 10.1016/s1386-6532(02)00049-5] [Cited by in Crossref: 123] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
3 Zhong JH, Li le Q, Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;CD008713. [PMID: 22161435 DOI: 10.1002/14651858.cd008713.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kuwahara R, Kumashiro R, Murashima S, Ogata K, Tanaka K, Hisamochi A, Hino T, Ide T, Tanaka E, Koga Y. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy. J Med Virol. 2004;72:26-34. [PMID: 14635007 DOI: 10.1002/jmv.10558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
5 Mansourian PG, Ghany MG, Thomas E. Spontaneous Mutations in the HBV Genome and their Clinical Implications. Curr Hepatitis Rep 2013;12:79-87. [DOI: 10.1007/s11901-013-0170-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol. 2002;37:824-830. [PMID: 12445424 DOI: 10.1016/s0168-8278(02)00281-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
7 Sharma P, Rakela J. Management of pre-liver transplantation patients?Part 1. Liver Transpl 2005;11:124-33. [DOI: 10.1002/lt.20353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
8 Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Soufleris K, Grammatikos N, Theodoropoulos K, Mpoumponaris A, Dona K, Zezos P, Nikolaidis N, Orfanou-koumerkeridou E, Balaska A, Eugenidis N. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol 2007;22:1582-8. [DOI: 10.1111/j.1440-1746.2007.05103.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
9 Cheng H, Zhang HZ, Shen WA, Liu YF, Ma FC. Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli. World J Gastroenterol 2003;9:513-5. [PMID: 12632508 DOI: 10.3748/wjg.v9.i3.513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis. 2008;40:603-617. [PMID: 18499540 DOI: 10.1016/j.dld.2008.03.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
11 Nakanishi H, Kurosaki M, Asahina Y, Onuki Y, Ueda K, Nishimura Y, Tsuchiya K, Kitamura T, Uchihara M, Miyake S, Enomoto N, Izumi N. Polymerase Domain B Mutation Is Associated with Hepatitis Relapse during Long-Term Lamivudine Therapy for Chronic Hepatitis B. Intervirology 2005;48:381-8. [DOI: 10.1159/000086065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
12 Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K, Koga H, Takao Y. Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Dig Dis Sci. 2008;53:2999-3006. [PMID: 18618250 DOI: 10.1007/s10620-008-0384-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1452] [Article Influence: 119.6] [Reference Citation Analysis]
14 Yu AS, Keeffe EB. Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Clinics in Liver Disease 2003;7:551-72. [DOI: 10.1016/s1089-3261(03)00044-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021;13:509-35. [PMID: 34163570 DOI: 10.4251/wjgo.v13.i6.509] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39 Suppl 1:S3-25. [PMID: 14708673 DOI: 10.1016/s0168-8278(03)00378-7] [Cited by in Crossref: 59] [Article Influence: 3.5] [Reference Citation Analysis]
17 Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol 2010;52:478-85. [PMID: 20185198 DOI: 10.1016/j.jhep.2010.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
18 Nogales M, Serrano M, Suárez E, Corpas R, Pérez L, Claro R, Jarana R, Romero-gómez M, Martín-mazuelos E. Determinación del genotipo del virus de la hepatitis B y detección de mutaciones de resistencia al tratamiento con lamivudina. Gastroenterología y Hepatología 2004;27:515-20. [DOI: 10.1016/s0210-5705(03)70518-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Geng Y, Wang X, Lu X, Wu X, Xu N, Han L, Xu J. Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy. Medicine (Baltimore) 2016;95:e2657. [PMID: 26844490 DOI: 10.1097/MD.0000000000002657] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107. [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x] [Cited by in Crossref: 1646] [Cited by in F6Publishing: 1414] [Article Influence: 96.8] [Reference Citation Analysis]
21 Selabe SG, Song E, Burnett RJ, Mphahlele MJ. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes. J Med Virol. 2009;81:996-1001. [PMID: 19382250 DOI: 10.1002/jmv.21479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, Bowden S, Desmond P, Locarnini SA. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology. 2003;37:27-35. [PMID: 12500185 DOI: 10.1053/jhep.2003.50012] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 5.1] [Reference Citation Analysis]
23 Buti M, Rodriguez-Frias F, Jardi R, Esteban R. Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J Clin Virol. 2005;34 Suppl 1:S79-S82. [PMID: 16461229 DOI: 10.1016/s1386-6532(05)80015-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
24 Paik YH, Kim JK, Kim DY, Park JY, Ahn SH, Han KH, Chon CY, Lee KS. Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. J Korean Med Sci. 2010;25:882-887. [PMID: 20514309 DOI: 10.3346/jkms.2010.25.6.882] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
25 Fontana RJ, Lok AS. Combination of HBIG and lamivudine-resistant mutations: a formula for trouble? Liver Transpl 2002;8:1082-4. [PMID: 12424727 DOI: 10.1053/jlts.2002.36238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
26 Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014;20:11595-617. [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
27 Cooley L, Sasadeusz J. Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. J Clin Virol 2003;26:185-93. [PMID: 12600650 DOI: 10.1016/s1386-6532(02)00117-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-1661. [PMID: 7477217 DOI: 10.2165/00002018-200225070-00004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
29 Saruc M, Ozden N, Turkel N, Ayhan S, Hock LM, Tuzcuoglu I, Yuceyar H. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci. 2003;92:1386-1395. [PMID: 12820143 DOI: 10.1002/jps.10401] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
30 Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol. 2005;43:72-77. [PMID: 15896869 DOI: 10.1016/j.jhep.2005.02.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
31 Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, Holdaway S, Samarasinghe D, Jackson K, Locarnini SA. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502-507. [PMID: 24801414 DOI: 10.1016/j.jhep.2014.04.038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 18.1] [Reference Citation Analysis]
32 Björnsdottir TB, Stanzeit B, Sällberg M, Löve A, Hultgren C. Changing prevalence of hepatitis B virus genotypes in Iceland. J Med Virol 2005;77:481-5. [PMID: 16254980 DOI: 10.1002/jmv.20480] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
33 Karayiannis P. Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther. 2004;2:745-760. [PMID: 15482237 DOI: 10.1586/14789072.2.5.745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
34 European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242. [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001] [Cited by in Crossref: 1092] [Cited by in F6Publishing: 960] [Article Influence: 84.0] [Reference Citation Analysis]
35 Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World J Hepatol. 2011;3:292-299. [PMID: 22216369 DOI: 10.4254/wjh.v3.i12.292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
36 Marrone A, Zampino R, Karayannis P, Cirillo G, Cesaro G, Guerrera B, Ricciotti R, del Giudice EM, Utili R, Adinolfi LE, Ruggiero G. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. Aliment Pharmacol Ther 2005;22:707-14. [PMID: 16197491 DOI: 10.1111/j.1365-2036.2005.02653.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
37 Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 2006;66:1831-51. [PMID: 17040114 DOI: 10.2165/00003495-200666140-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
38 Orlando R, Tosone G, Portella G, Veropalumbo E, D'Onofrio M, Piazza M. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report. Infection 2008;36:472-4. [PMID: 17962902 DOI: 10.1007/s15010-007-7073-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
39 Kuo A, Gish R. Chronic Hepatitis B Infection. Clinics in Liver Disease 2012;16:347-69. [DOI: 10.1016/j.cld.2012.03.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
40 Vincenti D, Solmone M, Garbuglia AR, Iacomi F, Capobianchi MR. A sensitive direct sequencing assay based on nested PCR for the detection of HBV polymerase and surface glycoprotein mutations. J Virol Methods 2009;159:53-7. [PMID: 19442845 DOI: 10.1016/j.jviromet.2009.02.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
41 Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005;11:4344-50. [PMID: 16038032 DOI: 10.3748/wjg.v11.i28.4344] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
42 Andreone P, Gramenzi A, Cursaro C, Biselli M, Cammà C, Trevisani F, Bernardi M. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat. 2004;11:439-442. [PMID: 15357649 DOI: 10.1111/j.1365-2893.2004.00564.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
43 Uribe LA, O’brien CG, Wong RJ, Gish RR, Tsai N, Nguyen MH. Current Treatment Guidelines for Chronic Hepatitis B and Their Applications. Journal of Clinical Gastroenterology 2014;48:773-83. [DOI: 10.1097/mcg.0000000000000130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009: Management of HBV: Consensus of JSH 2009. Hepatology Research 2011;41:1-21. [DOI: 10.1111/j.1872-034x.2010.00739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Yuen MF, Lai CL. Prediction of treatment outcomes for lamivudine. J Gastroenterol Hepatol 2007;22:964-5. [PMID: 17608839 DOI: 10.1111/j.1440-1746.2007.05007.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
48 Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734-40. [PMID: 12019083 DOI: 10.1128/AAC.46.6.1734-1740.2002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
49 Nikolaidis NL, Giouleme OI, Tziomalos KA, Saveriadis AS, Grammatikos N, Doukelis P, Voutsas AD, Vassiliadis T, Patsiaoura K, Orfanou-koumerkeridou E, Balaska A, Eugenidis NP. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients. J Gastroenterol Hepatol 2005;20:1721-5. [DOI: 10.1111/j.1440-1746.2005.04029.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
50 Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies. Medicine (Baltimore) 2019;98:e15297. [PMID: 31027094 DOI: 10.1097/MD.0000000000015297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
51 Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001;8:311-321. [PMID: 11555188 DOI: 10.1046/j.1365-2893.2001.00303.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
52 Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57-63. [PMID: 14687142 DOI: 10.1046/j.1572-0241.2003.04021.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
53 Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002;293:305-313. [PMID: 11886250 DOI: 10.1006/viro.2001.1246] [Cited by in Crossref: 147] [Cited by in F6Publishing: 144] [Article Influence: 7.7] [Reference Citation Analysis]
54 Wu F, Wu MJ, Zhuge XL, Zhu SM, Zhu B. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int 2012;11:172-6. [PMID: 22484586 DOI: 10.1016/s1499-3872(12)60144-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
55 Fung SK, Wong FS, Wong DK, Hussain MT, Lok AS. Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int. 2006;26:796-804. [PMID: 16911461 DOI: 10.1111/j.1478-3231.2006.01297.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
56 Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010;14:e1024-e1031. [PMID: 20870439 DOI: 10.1016/j.ijid.2010.06.013] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 10.6] [Reference Citation Analysis]
57 Ishigami M, Honda T, Ishizu Y, Onishi Y, Kamei H, Hayashi K, Ogura Y, Hirooka Y, Goto H. Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients. Liver Transpl. 2014;20:1211-1220. [PMID: 24961506 DOI: 10.1002/lt.23935] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
58 Fontana RJ. Management of Decompensated HBV Cirrhosis: Lamivudine and Beyond. Am J Gastroenterol 2004;99:64-7. [DOI: 10.1111/j.1572-0241.2004.04032.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
59 Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatology Research 2010;40:14-30. [DOI: 10.1111/j.1872-034x.2009.00601.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 73] [Article Influence: 12.3] [Reference Citation Analysis]
60 Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis 2004;8:321-52, vi. [PMID: 15481343 DOI: 10.1016/j.cld.2004.02.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
61 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 1982] [Article Influence: 240.8] [Reference Citation Analysis]
62 Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, Hussain M, Cursaro C, Richtmyer P, Marrero JA, Lok AS. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. Journal of Hepatology 2005;43:937-43. [DOI: 10.1016/j.jhep.2005.05.037] [Cited by in Crossref: 143] [Cited by in F6Publishing: 125] [Article Influence: 8.9] [Reference Citation Analysis]
63 Vassiliadis T, Nikolaidis N, Giouleme O, Tziomalos K, Grammatikos N, Patsiaoura K, Zezos P, Gkisakis D, Theodoropoulos K, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005;21:531-7. [PMID: 15740536 DOI: 10.1111/j.1365-2036.2005.02388.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
64 Shin JW, Chung YH, Choi MH, Kim JA, Ryu SH, Jang MK, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy. J Gastroenterol Hepatol 2005;20:844-9. [PMID: 15946130 DOI: 10.1111/j.1440-1746.2005.03824.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
65 Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007;45:1179-1186. [PMID: 17465002 DOI: 10.1002/hep.21581] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
66 Niro GA, Santantonio T, Fontana R, Insalata M, Facciorusso D, Signorile F, Perri F, Guastadisegni A, Gioffreda D, Palmieri O, Pastore G, Andriulli A. Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine: LAMIVUDINE RE-TREATMENT IN ANTI-HBe+ CHRONIC HEPATITIS B. Alimentary Pharmacology & Therapeutics 2003;18:933-40. [DOI: 10.1046/j.1365-2036.2003.01787.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
67 Homs M, Buti M, Quer J, Jardí R, Schaper M, Tabernero D, Ortega I, Sanchez A, Esteban R, Rodriguez-Frias F. Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res 2011;39:8457-71. [PMID: 21742757 DOI: 10.1093/nar/gkr451] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
68 Yim HJ. [Hepatitis B virus genetic diversity and mutant]. Korean J Hepatol. 2008;14:446-464. [PMID: 19119240 DOI: 10.3350/kjhep.2008.14.4.446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
69 Xiao LX, Chen YR, Huang P, Mei YY, Pan CQ, Lin CS. The safety of antiviral therapy and drug withdrawal for the prevention of mother-to-child transmission of HBV during pregnancy. J Med Virol 2020. [PMID: 32410298 DOI: 10.1002/jmv.26011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Manolakopoulos S, Bethanis S, Elefsiniotis J, Karatapanis S, Triantos C, Sourvinos G, Touloumi G, Economou M, Vlachogiannakos J, Spandidos D, Avgerinos A, Tzourmakliotis D. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther 2006;23:787-95. [DOI: 10.1111/j.1365-2036.2006.02806.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
71 Du QW, Ding JG, Sun QF, Hong L, Cai FJ, Zhou QQ, Wu YH, Fu RQ. Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. Med Sci Monit. 2013;19:751-756. [PMID: 24019010 DOI: 10.12659/msm.889443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
72 Lim LG, Aung MO, Seet BL, Tan C, Dan YY, Lee YM, Sutedja DS, Fernandes M, Lee GH, Koay E, Lim SG. Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance. World J Gastroenterol 2010;16:4691-6. [PMID: 20872970 DOI: 10.3748/wjg.v16.i37.4691] [Reference Citation Analysis]
73 Belyhun Y, Liebert UG, Maier M. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia. PLoS One 2018;13:e0191970. [PMID: 29408943 DOI: 10.1371/journal.pone.0191970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Lu P, Liu J, Wang Y, Chen X, Yang Y, Ji R. Design, synthesis and evaluation of novel oxazaphosphorine prodrugs of 9-(2-phosphonomethoxyethyl)adenine (PMEA, adefovir) as potent HBV inhibitors. Bioorg Med Chem Lett 2009;19:6918-21. [PMID: 19889538 DOI: 10.1016/j.bmcl.2009.10.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
75 Forton D, Karayiannis P. Established and emerging therapies for the treatment of viral hepatitis. Dig Dis 2006;24:160-73. [PMID: 16699274 DOI: 10.1159/000090319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
76 Stornaiuolo G, Stanzione M, Brancaccio G, Cuomo G, Precone V, Di Biase S, Felaco FM, Piccinino F, Gaeta GB. Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B. World J Gastroenterol 2007;13:5642-7. [PMID: 17948940 DOI: 10.3748/wjg.v13.i42.5642] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B. Gut Liver 2010;4:212-8. [PMID: 20559524 DOI: 10.5009/gnl.2010.4.2.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Reddy KR, Colby TJ, Fujitaki JM, van Poelje PD, Erion MD. Liver targeting of hepatitis-B antiviral lamivudine using the HepDirect prodrug technology. Nucleosides Nucleotides Nucleic Acids 2005;24:375-81. [PMID: 16247954 DOI: 10.1081/ncn-200059781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
79 Rizzetto M, Marzano A, Lagget M. Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine. J Hepatol. 2003;39 Suppl 1:S168-S171. [PMID: 14708698 DOI: 10.1016/s0168-8278(03)00311-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
80 Reddy KR, Matelich MC, Ugarkar BG, Gómez-Galeno JE, DaRe J, Ollis K, Sun Z, Craigo W, Colby TJ, Fujitaki JM, Boyer SH, van Poelje PD, Erion MD. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J Med Chem 2008;51:666-76. [PMID: 18173234 DOI: 10.1021/jm7012216] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
81 Buti M, Jardi R, Rodriguez-frias F, Valdes A, Schaper M, Esteban R, Guardia J. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy. Aliment Pharmacol Ther 2005;21:1349-56. [DOI: 10.1111/j.1365-2036.2005.02503.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
82 Murakami R, Amada N, Sato T, Orii T, Kikuchi H, Haga I, Ohashi Y, Okazaki H. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience. Clin Transplant 2006;20:351-8. [DOI: 10.1111/j.1399-0012.2006.00490.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
83 Buti M, Cotrina M, Jardi R, de Castro EC, Rodriguez-Frias F, Sánchez-Avila F, Esteban R, Guardia J. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat. 2001;8:270-275. [PMID: 11454178 DOI: 10.1046/j.1365-2893.2001.00296.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
84 Sarin SK, Satapathy SK, Chauhan R. Hepatitis B e-antigen negative chronic hepatitis B. J Gastroenterol Hepatol 2002;17 Suppl 3:S311-21. [PMID: 12472956 DOI: 10.1046/j.1440-1746.17.s3.20.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
85 Lin C, Liao L, Wang C, Chen P, Lai M, Chen D, Kao J. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. Liver Int 2004;24:9-15. [DOI: 10.1111/j.1478-3231.2004.00893.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
86 Asselah T, Lada O, Boyer N, Martinot M, Marcellin P. [Treatment of chronic hepatitis B]. Gastroenterol Clin Biol. 2008;32:749-768. [PMID: 18775613 DOI: 10.1016/j.gcb.2008.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
87 Du L, Wu L, Jin Y, Jia J, Li M, Wang Y. Self-assembled drug delivery systems. Part 7: Hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release. International Journal of Pharmaceutics 2014;472:1-9. [DOI: 10.1016/j.ijpharm.2014.06.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
88 Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, Schinazi RD, Korba BE, Cote PJ, Gerin JL. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology. 2004;127:S283-S293. [PMID: 15508096 DOI: 10.1053/j.gastro.2004.09.043] [Cited by in Crossref: 103] [Cited by in F6Publishing: 89] [Article Influence: 6.1] [Reference Citation Analysis]
89 Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703-712. [PMID: 16941700 DOI: 10.1002/hep.21290] [Cited by in Crossref: 190] [Cited by in F6Publishing: 169] [Article Influence: 12.7] [Reference Citation Analysis]
90 Yuki N, Nagaoka T, Nukui K, Omura M, Hikiji K, Kato M. Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection. J Gastroenterol 2008;43:457-63. [DOI: 10.1007/s00535-008-2174-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
91 Vassiliadis T, Patsiaoura K, Tziomalos K, Gkiourtzis T, Giouleme O, Grammatikos N, Rizopoulou D, Nikolaidis N, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006;12:2417-22. [PMID: 16688836 DOI: 10.3748/wjg.v12.i15.2417] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
92 Conzelmann I, Wintermeyer P, Wirth S, Radke R, Gerner P. Complete hepatitis B virus genome analysis in chronically infected children before and during lamivudine treatment. J Med Virol. 2005;77:194-202. [PMID: 16121374 DOI: 10.1002/jmv.20436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-35. [PMID: 15280461 DOI: 10.1128/JVI.78.16.8524-8535.2004] [Cited by in Crossref: 84] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
94 Mao H, Wang H, Zhang D, Mao H, Zhao J, Shi J, Cui Z. Study of hepatitis B virus gene mutations with enzymatic colorimetry-based DNA microarray. Clinical Biochemistry 2006;39:67-73. [DOI: 10.1016/j.clinbiochem.2005.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
95 Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, Pan Y, Zhang H, Jiang J, Niu J. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011;31:1118-1126. [PMID: 21745278 DOI: 10.1111/j.1478-3231.2011.02507.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
96 European Association For The Study Of The Liver. [EASL clinical practice guidelines. Management of chronic hepatitis B]. Gastroenterol Clin Biol. 2009;33:539-554. [PMID: 19481389 DOI: 10.1016/j.gcb.2009.03.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
97 Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104:435-443. [PMID: 30733266 DOI: 10.3324/haematol.2018.210252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
98 Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat. 2002;9:52-61. [PMID: 11851903 DOI: 10.1046/j.1365-2893.2002.00304.x] [Cited by in Crossref: 245] [Cited by in F6Publishing: 213] [Article Influence: 12.9] [Reference Citation Analysis]
99 Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. J Clin Gastroenterol. 2007;41:403-411. [PMID: 17413611 DOI: 10.1097/01.mcg.0000248018.08515.f9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
100 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
101 Baha W, Ennaji MM, Lazar F, Melloul M, El Fahime E, El Malki A, Bennani A. HBV genotypes prevalence, precore and basal core mutants in Morocco. Infection, Genetics and Evolution 2012;12:1157-62. [DOI: 10.1016/j.meegid.2012.04.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
102 Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol. 2014;20:7644-7652. [PMID: 24976702 DOI: 10.3748/wjg.v20.i24.7644] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
103 Liu C, Chen P, Lai M, Kao J, Chang C, Wu H, Shau W, Chen D. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003;124:80-90. [DOI: 10.1053/gast.2003.50003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 2.7] [Reference Citation Analysis]
104 Laubscher B, Gehri M, Roulet M, Wirth S, Gerner P. Survival of infantile fulminant hepatitis B and treatment with Lamivudine. J Pediatr Gastroenterol Nutr. 2005;40:518-520. [PMID: 15795605 DOI: 10.1097/01.mpg.0000144374.63230.44] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
105 Liaw YF. The current management of HBV drug resistance. J Clin Virol. 2005;34 Suppl 1:S143-S146. [PMID: 16461216 DOI: 10.1016/s1386-6532(05)80025-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
106 Koziel MJ, Thio CL. Hepatitis B Virus and Hepatitis Delta Virus. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2059-86. [DOI: 10.1016/b978-0-443-06839-3.00146-6] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
107 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
108 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1-58. [PMID: 24397839 DOI: 10.1111/hepr.12269] [Cited by in Crossref: 103] [Cited by in F6Publishing: 89] [Article Influence: 14.7] [Reference Citation Analysis]
109 Gao S, Duan ZP, Coffin CS. Clinical relevance of hepatitis B virus variants. World J Hepatol 2015;7:1086-96. [PMID: 26052397 DOI: 10.4254/wjh.v7.i8.1086] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
110 Jazayeri SM, Alavian SM, Dindoost P, Thomas HC, Karayiannis P. Molecular Variants of Hepatitis B Surface Antigen (HBsAg). In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 107-26. [DOI: 10.1002/9781118637272.ch8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology. 2002;36:219-226. [PMID: 12085368 DOI: 10.1053/jhep.2002.33894] [Cited by in Crossref: 144] [Cited by in F6Publishing: 133] [Article Influence: 7.6] [Reference Citation Analysis]
112 Araujo NM, Branco-Vieira M, Silva AC, Pilotto JH, Grinsztejn B, de Almeida AJ, Trepo C, Gomes SA. Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Hepatol Res. 2008;38:1194-1203. [PMID: 18624719 DOI: 10.1111/j.1872-034x.2008.00392.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
113 Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology. 2002;299:88-99. [PMID: 12167344 DOI: 10.1006/viro.2002.1448] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 5.1] [Reference Citation Analysis]
114 Huy TTT, Ushijima H, Quang VX, Ngoc TT, Hayashi S, Sata T, Abe K. Characteristics of core promoter and precore stop codon mutants of hepatitis B virus in Vietnam. J Med Virol 2004;74:228-36. [DOI: 10.1002/jmv.20175] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
115 Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325-1332. [PMID: 24162593 DOI: 10.1136/gutjnl-2013-305517] [Cited by in Crossref: 186] [Cited by in F6Publishing: 165] [Article Influence: 23.3] [Reference Citation Analysis]
116 Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol. 2003;13:255-272. [PMID: 12820187 DOI: 10.1002/rmv.393] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
117 Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol. 2002;97:1618-1628. [PMID: 12135009 DOI: 10.1111/j.1572-0241.2002.05819.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 73] [Article Influence: 4.8] [Reference Citation Analysis]
118 Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat. 2005;12:398-404. [PMID: 15985011 DOI: 10.1111/j.1365-2893.2005.00613.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
119 Chang UI, Lee YC, Wie SH, Jang JW, Bae SH, Choi JY, Yang JM, Yoon SK, Sun HS. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy. J Med Virol 2007;79:902-10. [PMID: 17516533 DOI: 10.1002/jmv.20819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
120 Brooks J, Gelson W, Rushbrook SM. Therapeutic advances in the management of chronic hepatitis B infection. Ther Adv Chronic Dis 2013;4:157-66. [PMID: 23819019 DOI: 10.1177/2040622313484647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
121 Alavian SM, Carman WF, Jazayeri SM. HBsAg variants: diagnostic-escape and diagnostic dilemma. J Clin Virol. 2013;57:201-208. [PMID: 22789139 DOI: 10.1016/j.jcv.2012.04.027] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
122 Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, Lagget M, Taak NK, Woessner MA, Gardner SD. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005;42:173-179. [PMID: 15664241 DOI: 10.1016/j.jhep.2004.10.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
123 Lu HY, Zeng Z, Xu XY, Zhang NL, Yu M, Gong WB. Mutations in surface and polymerase gene of chronic hepatitis B patients with coexisting HBsAg and anti-HBs. World J Gastroenterol 2006;12:4219-23. [PMID: 16830379 DOI: 10.3748/wjg.v12.i26.4219] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
124 Hui CK, Lau GK. Immune system and hepatitis B virus infection. J Clin Virol. 2005;34 Suppl 1:S44-S48. [PMID: 16461223 DOI: 10.1016/S1386-6532(05)80009-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
125 Thompson AJV, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, Chen RYM, Demediuk B, Shaw G, Bell SJ, Watson KJR, Locarnini SA, Desmond PV. Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factors. J Gastroenterol Hepatol 2007;22:1078-85. [DOI: 10.1111/j.1440-1746.2006.04630.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
126 Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology. 2004;39:64-73. [PMID: 14752824 DOI: 10.1002/hep.20019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
127 Lee S, Park JY, Kim do Y, Kim BK, Kim SU, Song K, Ku HJ, Han KH, Ahn SH. Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. J Med Virol. 2016;88:1027-1034. [PMID: 26538234 DOI: 10.1002/jmv.24427] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
128 Kazim SN, Sarin SK, Sharma BC, Khan LA, Hasnain SE. Characterization of naturally occurring and Lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India. Intervirology. 2006;49:152-160. [PMID: 16428891 DOI: 10.1159/000089376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
129 Gaia S, Marzano A, Smedile A, Barbon V, Abate ML, Olivero A, Lagget M, Paganin S, Fadda M, Niro G. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2004;20:281-287. [PMID: 15274664 DOI: 10.1111/j.1365-2036.2004.02073.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
130 Liaw Y. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B: Management of YMDD mutations. Journal of Gastroenterology and Hepatology 2002;17:S333-7. [DOI: 10.1046/j.1440-1746.17.s3.23.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
131 Zoulim F, Trépo C. Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology. 2000;32:1172-1174. [PMID: 11050072 DOI: 10.1053/jhep.2000.20150] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
132 Hui JM, George J, Liddle C, Lin R, Samarasinghe D, Crewe E, Farrell GC. Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. Am J Gastroenterology 2002;97:1003-9. [DOI: 10.1111/j.1572-0241.2002.05621.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
133 Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, Nejabat M, Khodadad M, Ardebili M. YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy. Hepat Mon 2015;15:e27120. [PMID: 26300928 DOI: 10.5812/hepatmon.27120v2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
134 Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res. 2007;37:94-100. [PMID: 17300703 DOI: 10.1111/j.1872-034x.2007.00013.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]